Sutro Biopharma, Inc.

Sutro Biopharma announced after the stock market closed on 13 March that as a result of a strategic portfolio review the company will end development of its one and only clinical-stage antibody drug c

Drug candidates that are in early development come with high levels of risk for pharma companies, but for Ipsen, this is well worth the potential reward. According to Mary Jane Hinrichs, senior vice p

Ipsen SA appears to have reset the market for US Food and Drug Administration priority review vouchers after selling its voucher to an unnamed company for $158m. Ipsen received the voucher, which can

Ipsen SA has shown itself to be a canny dealmaker over the past few years and its negotiating skills have been shown again with the sale of a priority review voucher (PRV) at well above market rate.